AIR 645

Drug Profile

AIR 645

Alternative Names: AIR645; ISIS-369645

Latest Information Update: 28 Mar 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Isis Pharmaceuticals
  • Developer Altair Therapeutics
  • Class Anti-inflammatories; Antiasthmatics; Antisense oligonucleotides; Oligonucleotides
  • Mechanism of Action Interleukin 13 inhibitors; Interleukin 4 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Allergic asthma; Asthma; Rhinitis

Most Recent Events

  • 31 Dec 2010 Isis Pharmaceuticals reacquires AIR 645 and related assets from Altair Therapeutics
  • 31 Dec 2010 Discontinued - Phase-I for Asthma in Canada (Inhalation)
  • 31 Dec 2010 Discontinued - Phase-II for Allergic asthma in Canada (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top